Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Ken, Maes"'
Autor:
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited treatment options and a high demand for novel targeted therapies. Since myeloid-related protein S100A9 is abundantly expressed in AML, we aimed to unravel the therapeutic i
Externí odkaz:
https://doaj.org/article/e3d2c809e45a47e385516477b86ed8c1
Autor:
Sofie Ryckx, Jean De Schepper, Philippe Giron, Ken Maes, Freya Vaeyens, Kaat Wilgenhof, Pierre Lefesvre, Caroline Ernst, Kim Vanderlinden, Daniel Klink, Frederik Hes, Jesse Vanbesien, Inge Gies, Willem Staels
Publikováno v:
Journal of Medical Case Reports, Vol 17, Iss 1, Pp 1-10 (2023)
Abstract Introduction Pure androgen-secreting adrenocortical tumors are a rare but important cause of peripheral precocious puberty. Case presentation Here, we report a pure androgen-secreting adrenocortical tumor in a 2.5-year-old boy presenting wit
Externí odkaz:
https://doaj.org/article/01db2d45dece4f3188e01c74f2bfb2c3
Autor:
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (comb
Externí odkaz:
https://doaj.org/article/c65a30545a9545fdbf7aa6e375ae1aa6
Autor:
Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 wa
Externí odkaz:
https://doaj.org/article/d2125622a63f49eba73f4bc280a4cd85
Autor:
Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are fr
Externí odkaz:
https://doaj.org/article/4a066c1d34e84d5fab2ce817a5f72403
Autor:
Ann De Becker, Robbe Heestermans, Wouter De Brouwer, Kara Bockstaele, Ken Maes, Ivan Van Riet
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Mesenchymal stromal cells (MSCs) are non-hematopoietic cells that have a broad therapeutic potential. To obtain sufficient cells for clinical application, they must be expanded ex vivo. In the initial expansion protocols described, fetal calf serum (
Externí odkaz:
https://doaj.org/article/33c1b6329ba94b0bb77c7a256b491d2c
Autor:
Philip Vlummens, Stefaan Verhulst, Kim De Veirman, Anke Maes, Eline Menu, Jérome Moreaux, Hugues De Boussac, Nicolas Robert, Elke De Bruyne, Dirk Hose, Fritz Offner, Karin Vanderkerken, Ken Maes
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here, we used bio-informatic tools to ide
Externí odkaz:
https://doaj.org/article/8c0741c3569949d7a42027200e618caa
Autor:
Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Yannick De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Quentin Lecocq, Edurne San José-Enériz, Stefaan Verhulst, Ken Maes, Karin Vanderkerken, Xabier Agirre, Felipe Prosper, Juan José Lasarte, Anna Mondino, Karine Breckpot
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promis
Externí odkaz:
https://doaj.org/article/f6044c9296d648419688c29e75e4e1a4
Autor:
Ken Maes, Anna Mondino, Juan José Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Karine Breckpot
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cancer cells are under the surveillance of the host immune system. Nevertheless, a number of immunosuppressive mechanisms allow tumors to escape protective responses and impose immune tolerance. Epigenetic alterations are central to cancer cell biolo
Externí odkaz:
https://doaj.org/article/dca51fd435da47f38cb8b04af97c44a6
Autor:
Philip Vlummens, Kim De Veirman, Eline Menu, Elke De Bruyne, Fritz Offner, Karin Vanderkerken, Ken Maes
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. In normal plasma cell development, cells undergo programmed DNA breaks and translocations, a process necessary for generation of
Externí odkaz:
https://doaj.org/article/29b02f99e9274eecaee42bda0b21d842